Differential expression of an alternative splice variant of IL-12Rβ1 impacts early dissemination in the mouse and associates with disease outcome in both mouse and humans exposed to tuberculosis

Mrinal K. Das¹, Aurelie A. Ray^{2*1}, Yi Cai³, Akul Singhania⁴, Christine M. Graham⁴, Mingfeng Liao^{2,5}, Jeffrey J. Fountain^{2,2}, John E. Pearl¹, Manish Pareek¹, Pranab Haldar¹, Anne O'Garra^{4,6}, Xinchun Chen³, Andrea M. Cooper^{1,6}.

¹Leicester Tuberculosis Research Group, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester UK.

^{2*1} Trudeau Institute Inc. Saranac Lake, NY USA, now at Transgene SA, Illkirch Graffenstaden Cedex France.

^{2*2} Trudeau Institute Inc., now at Centers for Disease Control, Atlanta, USA.

³ Department of Pathogen Biology, Shenzhen University School of Medicine, Shenzhen, China

⁴ The Francis Crick Institute, London, UK

⁵ Guangdong Key Lab for Diagnosis & Treatment of Emerging Infectious Diseases, Shenzhen Key Lab of Infection & Immunity, Shenzhen Third People's Hospital, jep , Shenzhen , China

⁶ National Heart and Lung Institute, Imperial College London, London, United Kingdom

⁷ Corresponding author: Andrea Cooper, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, LE1 7RH, UK.

Email: amc72@le.ac.uk

Keywords: Tuberculosis, IL-12Rβ1, alternative splice, transcriptional analysis, dissemination.

25 Grant support: **MKD** – Newton Fellowship; **AAR, JJF, JEP, AMC** were supported by Trudeau Institute,
 26 Inc. NIAID grant AI067723, The Royal Society to AMC; **AOG, CMG** and **AS** were funded by The Francis
 27 Crick Institute, (Crick 10126; Crick 10468), which receives its core funding from Cancer Research UK,
 28 the U.K. Medical Research Council, and the Wellcome Trust; and the sequencing project by the Bioaster
 29 Microbiology Technology Institute, Lyon, France; Medical Diagnostic Discovery Department, bioMérieux
 30 SA, Marcy l'Etoile, France; and funded in part by Illumina Inc., San Diego, CA, USA. AAR

31 **Abstract.** (244 words)

32 Experimental mouse models of TB suggest that early events in the lung impact immunity. Early events
 33 in the human lung in response to TB are difficult to probe and their impact on disease outcome is
 34 unknown. We have shown in mouse that a secreted alternatively-spliced variant of IL-12R β 1, lacking the
 35 transmembrane domain and termed Δ TM-IL-12R β 1, promotes dendritic cell migration to the draining
 36 lymph node, augments T cell activation and limits dissemination of *M. tuberculosis* (Mtb). We show here
 37 that CBA/J and C3H/HeJ mice (both highly susceptible to Mtb) express higher levels of Δ TM-IL-12R β 1
 38 than resistant C57BL/6 mice and limit early dissemination of Mtb from the lungs. Both CD11c⁺ cells and
 39 T cells express Δ TM-IL-12R β 1 in humans, and mice unable to make Δ TM-IL-12R β 1 in either CD4 or
 40 CD11c expressing cells permit early dissemination from the lung. Analysis of publically available blood
 41 transcriptomes indicates that pulmonary TB is associated with high Δ TM-IL-12R β 1 expression and that
 42 of all IL-12 related signals, the Δ TM-IL-12R β 1 signal best predicts active disease. Δ TM-IL-12R β 1
 43 expression reflects the heterogeneity of latent TB infection and has the capacity to discriminate between
 44 latent and active disease. In a new Chinese TB patient cohort, Δ TM-IL-12R β 1 effectively differentiates
 45 TB from latent TB, healthy controls and pneumonia patients. Finally, Δ TM-IL-12R β 1 expression drops in
 46 drug-treated individuals in the UK and China where infection pressure is low. We propose that Δ TM-IL-
 47 12R β 1 regulates early dissemination from the lung and that it has diagnostic potential and provides
 48 mechanistic insights into human TB.

49

Introduction

Tuberculosis (TB) remains a critical worldwide health issue despite significant public health and research efforts¹. Key elements in our failure to limit this disease are the large number of people infected with the bacterium, *Mycobacterium tuberculosis* (Mtb) which causes disease, the lack of an effective vaccine against pulmonary TB and the need for prolonged and multiple drug treatments². A critical gap in knowledge is what separates those that develop disease from the majority of infected individuals who control the infection without consequences³. Mendelian susceptibility to mycobacterial disease (MSMD) provides some insight, as those lacking the ability to generate or respond to interferon (IFN)-γ have a significantly increased risk of mycobacterial disease including TB⁴. A key component identified by MSMD and one known to exacerbate severity of TB is genetic dysfunction of the Interleukin (IL)-12 receptor component IL-12Rβ1^{4, 5}, which acts with IL-12Rβ2 or IL-23R to mediate signaling by IL-12p70 or IL-23 respectively⁶. Understanding how the IL-12 receptor complex contributes to protection and disease is therefore critical. While the major function of this receptor complex is to promote IFN-γ production and consequent macrophage activation^{4, 6}, we have identified a novel role for IL-12p40 and IL-12Rβ1 in initiation of early events within the lung following low dose aerosol exposure to Mtb^{7, 8}. Experimental mouse models of aerosol exposure to Mtb indicate that the rapidity of bacterial dissemination and early activation of T cells in the draining lymph node and spleen contribute to effective control of lung infection^{9, 10, 11}. Specifically, slow dissemination of bacteria leads to delayed T cell activation and delayed recruitment of these T cells¹². This delay results in T cells arriving at the infected foci after the inflammatory response to the bacteria has begun and where the inflamed environment limits the efficacy of the T cell response in situ^{10, 13}. We have shown that the cytokine IL-12p40 is expressed early following Mtb exposure⁸ and that if dendritic cells do not express IL-12p40 then they do not become motile when exposed to Mtb, do not migrate from the lung to the draining lymph node and do not drive naive T cell activation⁷. Dendritic cells in the lungs of Mtb-exposed mice produce not only IL-12p40 but also an alternative splice variant of IL-12Rβ1 which lacks the transmembrane domain and which we have called ΔTM-IL-12Rβ1⁸. This splice variant was identified when the receptor was first described¹⁴ however

its function was not appreciated until our studies in Mtb^{8, 15}. The ΔTM-IL-12Rβ1 locates to the endoplasmic reticulum¹⁶ and can be secreted by transfected cells and mitogen-activated T cells blasts¹⁵. Human cells produce a similar splice variant of the IL12RB1 gene in response to Mtb exposure and this is referred to as isoform 2^{8, 17} and has been shown to augment human T cell responsiveness to IL-12p70¹⁸. Our data supports the hypothesis that the alternative splice variant of IL-12Rβ1 plays an early role in initiation of T cell activation in response to aerosol infection with Mtb and that the production of this splice variant in human TB merits investigation.

We have used meta-analysis of public data sets with statistical analysis to combine results from independent but related studies to identify factors potentially contributing to human disease¹⁹. Meta-analysis of gene expression data in particular can provide support for further investigation of any one particular pathway by targeted differential expression analysis²⁰, analysis of relative expression of gene in various tissues and cells²¹ and pathway analysis²². Multiple transcriptomic profiles of TB patients and controls have been deposited for analysis²³. These data sets are available from areas of the world where the chance of infection (or infection pressure) varies due to the incident rate of disease; thus South Africa has a high incidence of TB at 781/100,000 and thus has high infection pressure, China has moderate incidence at 65/100,000 (modest infection pressure) and the UK has an overall low incidence (10/100,000) with some higher areas in London and the Midlands but at best only a low infection pressure¹. This variety in the source of transcriptomic data sets allows for global insight into how specific gene expression profiles are associated with disease and also allows infection pressure to be considered as a factor in this association. Importantly for our study, while the commercially available arrays have probes sets specific for IL12RB1 these sets contain probes uniquely specific for either the full length or the alternatively spliced isoform. Combining the signal for the full and the alternatively spliced isoform into one signal for IL12RB1 obfuscates which isoform is expressed and therefore manual curation is required in order to differentiate these signals.

To address the potential role of the alternative splice variant of IL-12Rβ1 in TB we have combined mouse mechanistic studies with analysis of both published and novel transcriptomic profiles. We have found that

high expression of Δ TM-IL-12R β 1 in the lungs of mice susceptible to Mtb results in very limited early dissemination of bacteria from the lung to the periphery. Furthermore, mice lacking the ability to make the Δ TM-IL-12R β 1 in either CD11c⁺ or CD4⁺ expressing cells are compromised in their ability to limit dissemination to the periphery. Taken together these data implicate early expression of the Δ TM-IL-12R β 1 as a factor in control of Mtb dissemination from the lung to the periphery. To determine if the human Δ TM-IL-12R β 1 or isoform 2 is associated with infection and disease in areas of low and high infection pressure we analyzed expression of the Δ TM-IL-12R β 1 specific probes in transcription data sets from around the world. We found that expression of Δ TM-IL-12R β 1 in the blood is associated with active pulmonary TB and that it reflects the heterogeneity of the latently infected population.

Materials and methods

Subjects and clinical sample collection. Protocols were approved by the Institutional Review Board of Shenzhen Third People's Hospital, Shenzhen, China and informed consent was obtained from all participants. Whole blood samples were collected from healthy controls (HC, n=20), individuals with latent tuberculosis infection (LTBI, n=20), patients with active tuberculosis (TB, n=20) and patients with pneumonia (n=20) at Shenzhen Third People's Hospital.

Patients with TB were diagnosed based on clinical symptoms, chest radiography, positive sputum Mtb culture and positive response to anti-TB chemotherapy. Asymptomatic individuals with non-clinical disease were recruited as controls. Mtb specific IGRAs were used to differentiate individuals with LTBI from HCs without infection²⁴. The diagnosis of pneumonia was based on 1) lavage fluid or sputum cultures were Mtb-negative during clinical follow-up, 2) new infiltration and clinical signs on chest radiograph were evident and completely resolved after treatment with the appropriate antibiotics, and 3) viral pathogens were not detected. The demographic characteristics of study populations of this study are in Table 1.

Mice C57BL/6J, C3H/HeJ and CBA/J mice were purchased from JAX mice and housed at Trudeau Institute, Inc. B6.Cg-Tg(CD4-Cre) and B6.Cg-Tg(Ilgax-cre) mice were purchased from Jax and crossed

128 with our transgenic mice, which upon FLP and CRE recombination excise introns 13 and 14 of the *il12rb1*
129 gene¹⁵. Confirmation of excision was undertaken with PCR in each case.

130 *Infection* Mtb strain H37Rv was grown in Proskauer Beck medium containing 0.05% Tween 80 to mid-
131 log phase and frozen at −70°C. Mice were infected with a low dose of bacteria (~75 CFU) using a Glas-
132 Col airborne infection system as previously described²⁵. At day 1 and day 15 post-challenge, mice were
133 killed by CO₂ asphyxiation, the organs were aseptically excised and individually homogenized in saline.
134 Organ homogenates were subsequently plated on nutrient 7H11 agar (BD Biosciences) for 3 weeks at
135 37°C, at which point CFU were counted.

136 *Quantitative PCR*. RNA was generated from mouse tissue or human cells using the RNAeasy kit and
137 was reverse transcribed with an RT Kit from Life technologies – now ThermoFisher Scientific). RT-PCR
138 was performed to generate Ct values which were normalized to the housekeeping gene signal and then
139 applied to a standard curve to determine copy number for each isoform of human and mouse IL-12Rβ1
140 transcript generated from a specific template²⁶.

141 *Human monocyte derived dendritic cells*. Discarded filters from blood donor clinic were harvested for
142 peripheral blood cells and the CD14+ cells were purified using magnetic beads (Miltenyi). CD14+ cells
143 were seeded at 2x10⁶/ml into wells in RPMI containing 10% FCS and stimulated with 4000IU/ml GM-CSF
144 and 1000IU/ml IL-4 (both cytokines from Peprotech). Media was refreshed at 3 days and the cells were
145 used for experiments at day 5.

146 *Microarray data from publically available databases*. To evaluate gene expression of ΔTM-IL-12Rβ1 in
147 TB, we used the transcriptome–microarray datasets available in public repositories. Briefly, public
148 databases of Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo>) and ArrayExpress
149 (<https://www.ebi.ac.uk/arrayexpress>) were searched with the keywords ‘Tuberculosis, Patients’. A total
150 of 59 data series (58 in GEO and 19 in ArrayExpress – with 16 overlapping) were retrieved from the
151 search. We used the following exclusion criteria:- samples other than blood or blood derived cells, array
152 platform lacking specific probe for ΔTM-IL-12Rβ1, series lacking non-comorbid TB conditions, lacking
153 adult TB subjects, with less than 3 replicated samples for one condition and repeat arrays, we identified

16 arrays for further analysis. Full texts of the associated articles were evaluated for details on patient selection, demographics, sampling and RNA analysis. Six out of 16 were further excluded as the median centered across samples was not zero²⁷ and final analysis was carried out on 10 datasets (Table 2).

Processing of microarray dataset. Out of 10 data sets, 7 were generated on Illumina and 3 were on the Affymetrix platform (Table 2). All 3 Affymetrix data series were generated on the same platform. The raw .cel files were converted to expression values using GC-RMA package read by 'affy' package on Bioconductor²¹. Associated packages and libraries used were "hgu133plus2.db", "hgu133plus2cdf". R-studio version-1.0.143.0 using Bioconductor libraries and R statistical packages were used for data analysis. Processed data matrices were exported into tab delimited txt files.

For Illumina data series matrix, those including non-log transformed and normalized data were analyzed using 'GEOquery' and 'lumi' package^{28, 29}. For datasets having transformed and normalized values in series matrix, raw (non-normalized data) data files were downloaded from the GEO_supplementary files followed by processing using 'lumi' package. Briefly, data sets were processed, background corrected, log-2 transformed and then normalized using 'quantile' method. The processed data file was saved as tab delimited .txt file.

RNA-seq data analysis. Raw paired-end RNA-seq data from Singhania et al.³⁰ for the Berry London cohort³¹ was subjected to quality control using FastQC (Babraham Bioinformatics) and MultiQC³². Trimmomatic v0.36 was used to remove adapters and filter raw reads below the 36 bases long and leading and trailing bases below quality 25³³. Paired filtered reads from Trimmomatic were aligned to the *Homo sapiens* genome Ensembl GRCh38 (release 86) using HISAT2 v2.0.4 with default settings and RF rna-strandedness³⁴. Gene transcripts representing multiple splice variants for each gene locus were assembled using StringTie v1.3.3 with default settings, using the -eB and stranded library fr-secondstrand parameters, and the reference genome mentioned above³⁵. The assembled transcriptomes were annotated and analyzed using the *bioconductor* package Ballgown³⁶ in R to obtain fragments per kilobase of transcript per million reads sequenced (FPKM) values³⁶.

QuantiGene RNA analysis Whole blood was collected directly into PAXgene Blood RNA tubes (BD Biosciences) from individuals classified as HC, LTBI, TB and pneumonia in Shenzhen's Third People's Hospital, China (Table 1). Total RNA was extracted using the PAXgene Blood RNA Kit (Qiagen) following the manufacturer's instructions. The purified RNA samples were processed and run on a custom Panomics QuantiGene 2.0 Multiplex array (Affymetrix) plate by the Shanghai Biotechnology Corporation (China, Shanghai). This plate was designed by the manufacturer with probes to simultaneously detect 31 target genes including IL12RB1. Gene expression was normalized to Housekeeping genes transcripts following the manufacturer's protocol (<http://www.panomics.com>).

Statistical analysis. Differences between the means of experimental groups were analyzed using the two tailed Student's *t*-test or ANOVA as appropriate. Paired *t* tests were used for the longitudinal data. Differences were considered significant where $P \leq 0.05$. Inherently logarithmic data was transformed for statistical analysis. Where bacterial numbers were below the limit of detection the samples were given the value of the limit of detection to allow analysis. Pearson correlation was used to assess interaction between probes within a dataset. Briefly lumi/GC-RMA processed intensity data were used to prepare a functional data matrix with selected variables, this data matrix was assessed in the 'Statistical Module' of the Metaboanalyst 3.0 online tool to calculate the Pearson Correlation Coefficient³⁷. Similarly, a modified data matrix with downselected variables was used for Receiver Operating Characteristic (ROC) curve analysis. The analysis was carried out in 'Biomarker Analysis' module of MetaboAnalyst 3.0 online tool³⁷. Classical univariate ROC curve analysis was used for calculation of the area under curve (AUC).

Results

Expression of Δ TM-IL-12R β 1 in the lung associates with reduced dissemination of Mtb from the lung to the periphery. We knew from our previous studies that the Δ TM-IL-12R β 1 message was induced early in the lungs of C57BL/6J (B6) mice exposed to low dose aerosol infection⁸. We also knew that the global inability to make the Δ TM-IL-12R β 1 resulted in increased dissemination of bacteria to the periphery and reduced ability to generate IFN- γ producing T cells^{15, 18}. We wanted to determine whether this observation

was unique to the resistant B6 strain of mouse or if there was differential expression in mice which are substantially more susceptible to the low dose aerosol challenge³⁸. To achieve this we infected resistant B6 and susceptible CBA/J (CBA) and C3H/HeJ (C3H) mice in the same aerosol chamber and determined bacterial burden (Fig 1 A) and expression of the full length and Δ TM-IL-12R β 1 (Fig 1B) at day 15 post infection. We found that while the bacterial burden in the lung was not markedly dissimilar between the strains of mice at this time point there was a much greater range of dissemination to the mediastinal lymph node (MLN) and that there was no detectable dissemination to the spleen or liver in the C3H and CBA mice (Fig 1A). When we measured the copy number of both full length and Δ TM-IL-12R β 1 mRNA by quantitative RT-PCR we found that while all three strains expressed a small but measurable amount of full length mRNA, the C3H and CBA mice made a much greater amount of Δ TM-IL-12R β 1 in their lungs than did the B6. While there was modest induction of the Δ TM-IL-12R β 1, the baseline level of mRNA for Δ TM-IL-12R β 1 was already high in both the CBA and C3H suggesting that expression may be regulated by a homeostatic factor unrelated to Mtb infection. Regardless of the mechanism that drives baseline induction of Δ TM-IL-12R β 1, it is clear that a high level of expression is associated with reduced dissemination of bacteria from the lung to the periphery.

Expression of Δ TM-IL-12R β 1 can be induced in human dendritic cells and is impacted by TB in myeloid cells and lymphocytes in blood. Having identified an association between high level expression of Δ TM-IL-12R β 1 and reduced dissemination in mice with increased susceptibility to TB we wanted to determine expression of Δ TM-IL-12R β 1 in specific cells in humans with and without TB. In a first study we extended our observation that human monocyte-derived dendritic cells express Δ TM-IL-12R β 1 in response to Mtb⁸ by determining the kinetics of the response to live Mtb exposure in monocyte-derived dendritic cells from several anonymous blood donors. By measuring the copy number of full length and Δ TM-IL-12R β 1 mRNA using quantitative RT-PCR we were able to generate a ratio between the two signals and compare the response of individual donors. We found that donors made a strong Δ TM-IL-12R β 1 response between 3 and 6 hours which waned by 9 hours (Fig 2 A). These data suggest that Mtb drives an acute but not prolonged expression of Δ TM-IL-12R β 1 in this cell type. We also probed the gene-expression array data

in monocytes, neutrophils and lymphocytes that had been isolated from the blood of healthy control and those with active pulmonary TB³¹. We found that the signal from the probe specific for the Δ TM-IL-12R β 1 was more highly expressed in monocytes and neutrophils from TB patients relative to controls (Fig 2 B) and that while the CD4 and CD8 T cell signals independently failed to achieve the statistical threshold for significance, when the data sets were combined and analyzed as T lymphocytes, they were significantly different (average log2 intensity: PTB 8.145 $\pm$ 0.10, n=14 versus HC 7.72 $\pm$ 0.16, n=8; P=0.0294). These data indicate that exposure to Mtb and active TB induces expression of Δ TM-IL-12R β 1 in human cells of both myeloid and lymphoid origin.

Inability of either CD11c or CD4 expressing cells to produce Δ TM-IL-12R β 1 results in increased dissemination of Mtb from the lung to the periphery following aerosol infection. We see expression of the Δ TM-IL-12R β 1 in both myeloid and lymphoid cells in blood from TB patients (Fig 2B) and we know that a global inability to make Δ TM-IL-12R β 1 reduces control of dissemination¹⁵ while high expression is associated with inhibition of dissemination of Mtb (Fig 1). We wanted therefore to determine whether myeloid or lymphoid cell expression of Δ TM-IL-12R β 1 is responsible for the control of dissemination of bacteria from the lung to the periphery. To do this we crossed our transgenic mouse, which excises exons 13 and 14 in a FLP/CRE dependent manner resulting in expression of the full length IL-12R β 1 without the structure to splice the Δ TM-IL-12R β 1¹⁵ to mice expressing Cre under the CD11c or CD4 promoter. We infected the mice via aerosol and determined bacterial burden in the lungs and periphery at day 15 post infection (Fig 2C). We found that while the bacterial burden in the lung was not affected by cell specific loss of Δ TM-IL-12R β 1 expression, there was a significant increase in the bacterial burden in the liver of mice lacking Δ TM-IL-12R β 1 in both CD11c and CD4 expressing cells (Fig 2C). While the mean number of bacteria in the MLN was not significantly different, the range of bacterial numbers was much increased for the mice lacking Δ TM-IL-12R β 1 in both CD11c- and CD4-expressing cells. Further, while significance was seen for increased dissemination to the spleen in mice lacking Δ TM-IL-12R β 1 in CD4-expressing cells, there was a trend to increased dissemination in the mice where Δ TM-IL-12R β 1 was deleted in CD11c⁺ cells. These data support the hypothesis that cells of both the lymphoid and myeloid

lineage produce Δ TM-IL-12R β 1 in response to infection and that while the lymphoid compartment seems to mediate the strongest effect, there is a measurable role for myeloid-derived Δ TM-IL-12R β 1 in TB control. In preliminary data we find that absence of Δ TM-IL-12R β 1 in CD11c expressing cells results in disruption of cytokine balance in the lung resulting in more IL-12p40 and more IL-10 (data not shown).

Meta-analysis of transcriptomic data reveals an association between PTB and expression of the Δ TM-IL-12R β 1 in human blood. We observe that Mtb induces Δ TM-IL-12R β 1 expression in human cells (Fig 2A) and that purified cells from the blood of TB patients express Δ TM-IL-12R β 1 (Fig 2B). We also observe an association between Δ TM-IL-12R β 1 expression and dissemination from the lung to the periphery in the experimental mouse model (Fig 1 and Fig 2C). Together the data support analysis of Δ TM-IL-12R β 1 expression in human disease. To achieve this we used defined criteria to select publically available array data sets and obtained 10 data sets from 5 countries, 3 continents and 4 platforms (Table 2)^{24, 31, 39, 40, 41}.

In both Illumina and Affymetrix array platforms there are 3 probes representing detection of IL12RB1 transcription, one of which is specific for the full length transcript, one specific for the Δ TM-IL-12R β 1 and one that can detect both. To determine what each of the probes contributes to the observed total IL12RB1 signal, we analyzed the raw data for each probe in 4 array data sets (Fig 3). This analysis revealed that for more than 90% of the samples, the signal from the probe specific for the full length IL-12R β 1 transcript is negligible (i.e. the raw probe signal is insignificant) (Fig 3, FL-IL12R β 1) while the signal for Δ TM-IL-12R β 1 is detectable in almost all samples (Fig 3, Δ TM-IL-12R β 1). The intensity of the signal for the probe specific for Δ TM-IL-12R β 1 is highly correlated with the signal from the probe which detects both the full length and Δ TM-IL-12R β 1 transcripts, while the signal for the probe specific for the full length transcript correlates with both signals to a much lower degree (Table 3). These analyses suggest that blood cells express the Δ TM-IL-12R β 1 transcript in significant amounts and that this transcript is the dominant one.

Higher expression of the Δ TM-IL-12R β 1 transcript correlates with pulmonary TB. We see a specific signal for Δ TM-IL-12R β 1 in transcriptional data sets from human blood (Fig 3) and we know that this molecule is associated with altered disease outcomes in the experimental mouse model (Fig 1 and 2). These

observations support an in depth analysis of the transcriptional data sets from individuals with pulmonary TB and their controls. To achieve this we processed, transformed and normalized the raw data from the transcriptional arrays identified in Table 2 and compared the signal to the sample groups defined by the investigators originating the data sets. The signal for the probe specific for Δ TM-IL-12R β 1 significantly differentiated PTB and control groups in all arrays tested in the UK³¹, China²⁴, Indonesia⁴⁰, Malawi³⁹ and South Africa³⁹ (Figure 4A). One data set in South Africa showed a trend but did not quite make significance (GSE19442)³¹ and the data in Indonesia⁴⁰ had a very small difference as might be expected as the only difference between the groups was the absence of active symptoms for TB (i.e. non TB rather than healthy control). Despite the small difference the data was not variable and thus reached significance statistically. These data demonstrate that Δ TM-IL-12R β 1 expression in the blood is associated with active pulmonary TB.

Expression of the splice variant in the blood reflects the heterogeneity of latent TB infection. While the Δ TM-IL-12R β 1 transcript clearly associates with pulmonary TB (PTB), it is variably able to discriminate between latent TB infection (LTB) and PTB (Fig 4A) with 3 of 7 studies showing discrimination but no association with location. One study showed very clear discrimination (China GSE 54992)²⁴ and this may reflect the fact that this resulted from isolated PBMC rather than whole blood or may just reflect the difference in the platform. These data suggest that the Δ TM-IL-12R β 1 may have the capacity to discriminate between LTB and PTB but work needs to be done to improve the signal. Within the three studies which showed the ability to discriminate between LTB and PTB we investigated whether the Δ TM-IL-12R β 1 signal was the strongest IL-12-related signal capable of discriminating between infection outcomes. To do this we generated a data matrix using array signals from IL12A, IL12B, IL12RB1 and IL-12RB2 as well as ratios of each set of signals as variables to see how well they differentiated between groups. The top three performing variables based on area under the curve (AUC) or receiver operating characteristic (ROC) curve capable of discriminating between control and PTB, LTB and PTB and LTB and control are shown in Table 4. The signal for Δ TM-IL-12R β 1 either alone or as a ratio with other members of the IL-12 family appears in the top three for all three arrays and for all three discriminatory

activities. These analyses demonstrate that the Δ TM-IL-12R β 1 signal has the potential to be a diagnostic tool and should be studied further.

To extend our analysis of array data we analyzed RNA-Seq data generated from the RNA used in the GSE19444 UK^{31,30} for transcription of Δ TM-IL-12R β 1 and found that as for array data, the Δ TM-IL-12R β 1 signal discriminates between PTB and controls, the Δ TM-IL-12R β 1 signal also discriminates between LTB and controls (Fig 4B). Importantly, we identify those samples identified as outliers in previous analyses^{31,30} by open circles (Fig 4B) which show low expression of Δ TM-IL-12R β 1 in the PTB outliers and high expression in 3 of 5 in the LTB outliers suggesting that the Δ TM-IL-12R β 1 signal may be associated with the discriminatory gene-signature identified previously^{31,30}.

Finally, we wanted to test the predictive and discriminatory power of the Δ TM-IL-12R β 1 signal in a test patient cohort in China. To do this we probed the RNA from whole human blood using a targeted array capable of measuring the IL-12R β 1 signal. We found that while the LTB cohort had a more variable signal than the controls, there was no significant difference between the means for these two populations and the IL-12R β 1-specific signal discriminated effectively between control and PTB, LTB and PTB, PTB and pneumonia (Fig 4C). These data further support the utility of the Δ TM-IL-12R β 1 signal to discriminate between PTB and LTB and PTB and other diseases.

The Δ TM-IL-12R β 1 signal decreases upon treatment in areas of low infection pressure. Because we see a difference in the Δ TM-IL-12R β 1 signal between controls and PTB we reasoned that the Δ TM-IL-12R β 1 may provide a signal indicating that treatment is effective. To determine if this was the case, we analyzed the transcriptome sets containing data from treated individuals from areas of low infection pressure (UK, overall incidence rate 10/100,000 – but with pockets of moderate infection pressure), moderate infection pressure (China, incidence rate 64/100,000) and high infection pressure (South Africa, incidence rate 781/100,000). We found that in the UK and China an early (8-12 weeks) drop in the Δ TM-IL-12R β 1 signal was seen during treatment, which was sustained long term (Fig 5, top graphs). In contrast, in two studies in South Africa no sustainable or reproducible drop in signal was seen over the population during treatment (Fig 5, bottom graphs). These data suggest that the signal for Δ TM-IL-12R β 1 may be useful to

detect treatment success in situations where the risk of reinfection is low, but it may reflect repeated infection where reinfection risk is high. Determining when and how the Δ TM-IL-12R β 1 is expressed in the lungs of those recently exposed to TB is therefore an important undertaking.

Discussion

We show here that the Δ TM-IL-12R β 1 is a significant indicator of active TB in human populations across the globe, that it can discriminate between latent and active TB under some conditions and that it drops during drug treatment in areas where the risk of reinfection is low. These observations are valuable and suggest that this gene transcription signal can contribute to the development of sensitive and specific modular transcriptional signatures³⁰ capable of defining the risk of TB development in those infected with the bacterium. The goal for these signatures is to eventually turn the marked heterogeneity of latent infection from a black box into a fully defined continuum with distinct transcriptional markers capable of allotting individuals into low, mid and high risk of progression. In addition to this goal however the data we report here also highlight the potential for the Δ TM-IL-12R β 1 signal to inform us about the mechanisms underlying the development and control of TB in the human lung.

In considering the early events in the TB-exposed lung, the invading bacteria is unlikely to meet any activated macrophages or T cells when it first arrives and thus for the acquired immune response to be initiated, the bacteria must migrate to the draining lymph node¹². This migration is slow to occur and this delay in activation and arrival of T cells allows the bacteria to grow unrestrained for up to 2 weeks in the B6 mouse^{9, 42}. Cytokines and chemokines capable of initiating early responses are therefore key to the rapidity of the response and to eventual outcome⁴³. We know that IL-12p40 is expressed very early following Mtb infection and that its production precedes production of IL-23 or IL-12p35 suggesting that it functions alone^{7, 8}. We also know that type 1 IFN, IL-1, IL-10 and IL-12 cross regulate each other in response to Mtb infection both in vitro and in vivo^{7, 44, 45, 46} and that the relative level of these cytokines at the initiation of infection has the potential to impact the initiation of immunity. Our data reported here suggest that the very high expression of the Δ TM-IL-12R β 1 in the C3H and CBA mice may sequester IL-

12p40, which we know aids in overcoming the IL-10-induced resistance to migration in Mtb-exposed dendritic cells ⁷. This inhibition may then severely limits the migration of bacteria from the lung to the periphery – as is seen in the CBA/J and C3H mice. In turn this delay then results in slow induction of T cells thus leading to the observed higher susceptibility of these mice strains to Mtb ³⁸. In contrast, total lack of the splice variant results in slightly higher dissemination of bacteria from the lung ¹⁵ and this effect can be seen if either myeloid or lymphoid cells lack the ΔTM-IL-12Rβ1. The increased effect of the absence of the ΔTM-IL-12Rβ1 in CD4 cells may reflect the role of the ΔTM-IL-12Rβ1 in augmenting IL-12p70-induced IFN-γ production in T cells^{15, 18}, while the impact of the loss of ΔTM-IL-12Rβ1 in the CD11c expressing cells may reflect the disruption of protective cytokine balance at the beginning of infection. The very early but short lived ΔTM-IL-12Rβ1 response of the human dendritic cells to live Mtb infection suggests that the signal is highly regulated and that sustained expression in myeloid cells may reflect ongoing exposure to live bacteria. In this regard, our data showing increased expression of ΔTM-IL-12Rβ1 signal in the blood of active TB patients suggests that myeloid cells expressing this signature may have been exposed to live bacteria in the recent past. Similarly, the drop in ΔTM-IL-12Rβ1 signal seen during drug treatment may reflect removal of live bacteria from the body and therefore the loss of stimulation for the signal. If one considers the infection pressure in the areas where the ΔTM-IL-12Rβ1 signal drops following drug treatment, it is possible that there is little re-exposure to drive the signal up again but in areas where re-infection is likely there will be repeated exposures in the lung and the ΔTM-IL-12Rβ1 will be maintained despite drug treatment. IL-12Rβ1 exhibits a marked degree of variability at the genomic⁵, transcriptional⁴⁷ and splice variant level¹⁷ suggesting that it is a highly flexible receptor with the capacity to both stimulate and inhibit cellular responses. Our observation that ΔTM-IL-12Rβ1 is secreted¹⁵ suggests that it acts to sequester cytokine and regulate activation of cells however it appears to drive activation of T cells ^{8, 18} and is a positive regulator of immunity. Its effects in mouse lungs suggests that, just as for type 1 IFN⁴⁸ a little bit is good and required for optimal control of bacterial dissemination but too much completely limits dissemination and hampers induction and expression of protective immunity.

387 Our data demonstrate that determining the underlying mechanisms whereby the alternative splice variant
388 of IL-12R β 1 impacts TB immunity in both mouse and man should be pursued. The data also support
389 further investigation into the best use of the transcriptional Δ TM-IL-12R β 1 signal in defining the
390 heterogeneity of latent TB infection.

Figure Legends

Figure 1 Mice susceptible to Mtb infection express high levels of Δ TM-IL-12R β 1 and limit early dissemination from the lung to the periphery. Mice were infected using an aerosol chamber capable of reproducibly delivering approximately 75 colony forming units to each mouse. Mice were housed for 15 days after challenge and then the organs plated for determination of colony forming units (CFU) (Fig 1A) and the copy number of mRNA for the full length IL-12R β 1 (FL-IL-12R β 1) and the alternative splice variant Δ TM-IL-12R β 1 determined by quantitative RT-PCR (Fig 1B). All data points are shown from 2 independent experiments (Fig 1A) or one data set representative of two total experiments (Fig 1B). Statistical significance was determined using one way ANOVA comparing all groups; n = 8 per group (Fig 1A) and n= 4 per group repeated twice (Fig 1B). *P<0.05, **P<0.01, ***P<0.001.

Figure 2 Δ TM-IL-12R β 1 is expressed by lymphoid and myeloid human cells and its absence in CD11c or CD4 expressing cells compromises control of dissemination in mice. Human myeloid derived dendritic cells were generated from anonymous blood donors and exposed to live Mtb for 24 hours. RNA was extracted over the time course and analyzed for the copy number of mRNA for the full length IL-12R β 1 (FL-IL-12R β 1) and the alternative splice variant Δ TM-IL-12R β 1 by quantitative RT-PCR. The ratio of Δ TM-IL-12R β 1 to FL-IL-12R β 1 was determined for each donor and the data points represent the mean of 4-7 values per time point (Fig 2A). Array data from GSE19443 was analyzed for expression of the Δ TM-IL-12R β 1 in cells purified from the blood of healthy controls (Cont) and TB patients (PTB). Data points are all shown with an n=4-7, the difference between the means was determined by Students *t* test, * P<0.05 (Fig 2B). Mice either intact (B6KI) lacking the ability to generate the Δ TM-IL-12R β 1 in either CD11c (CD11cCre) or CD4 (CD4Cre) expressing cells were infected with Mtb and the bacterial burden determined at day 15 as described for Fig 1. All data points are shown for 2 independent experiments, n=8, differences between the mean were determined by ANOVA with all columns being compared. *P<0.05, **P<0.01, ***P<0.001 (Fig 2C).

Figure 3. The majority of the IL-12R β 1 signal seen in microarray data is derived from the Δ TM-IL-12R β 1 specific probe. Raw data was manually curated and the signal for each probe analyzed

separately for each of 4 microarray data sets. The raw fluorescent intensity for each sample and different IL-12R β 1 isoform specific probe is shown. The probe intensity for the FL-IL-12R β 1 was not considered to be significant for the majority of samples and over all of the data sets whereas the signal from the probe specific for the Δ TM-IL-12R β 1 was significantly expressed in all samples.

Figure 4. Expression of Δ TM-IL-12R β 1 in blood associates with active pulmonary TB and is variably associated with latent TB. Microarray data from publically available databases was analyzed for the signal specific for Δ TM-IL-12R β 1 (Fig 4A). All data points are shown and the differences between the means of the Δ TM-IL-12R β 1 signal for each group determined by ANOVA with Tukey's multiple comparison, n=6-31, *P<0.05, **P<0.01, ***P<0.001. RNA-Seq data sets from a UK cohort was analyzed for expression of the Δ TM-IL-12R β 1 (Fig 4B) (all data points are shown with known group outliers shown as open symbols) and was discriminatory for controls versus both LTB and PTB, using ANOVA with Tukey's multiple comparison, n=12-21, *P<0.05, **P<0.01. RNA was taken from a new cohort in China and analyzed for expression of all IL-12R β 1 transcripts and was shown to discriminate between controls and LTB and PTB, between LTB and PTB and between PTB and pneumonia, using ANOVA with Tukey's multiple comparison, all data points are shown, n=20, *P<0.05, ***P<0.001.

Figure 5. Expression of Δ TM-IL-12R β 1 in blood associates drug treatment in areas of low to moderate infection pressure but fails in areas where infection pressure is high. Publically available array data was analyzed for the expression of Δ TM-IL-12R β 1 in the blood of TB-infected individuals undergoing drug treatment. All data points are shown and the ability of the signal to differentiate between pretreatment and a short and longer period post treatment determined. Paired *t* test was used to compare values at 0 and 6 or 8 week and 0 and 26 or 52 weeks for each patient. In the UK and China (top graphs) significant differences in the means were observed after treatment whereas no discernable effect could be seen in the South African cohorts undergoing treatment, n=7-27 P<0.05, **P<0.01.

References

1. WHO. Global Tuberculosis Report. Switzerland: World Health Organization; 2017.
2. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. *Annu Rev Public Health* 2013, **34**: 271-286.
3. Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, *et al.* The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. *Nat Rev Micro* 2009, **7**(12): 845-855.
4. Boisson-Dupuis S, Bustamante J, El-Baghdadi J, Camcioglu Y, Parvaneh N, El Azbaoui S, *et al.* Inherited and acquired immunodeficiencies underlying tuberculosis in childhood. *Immunol Rev* 2015, **264**(1): 103-120.
5. de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, *et al.* Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. *Medicine* 2010, **89**: 381-402.
6. Watford W, Hissong B, Bream J, Kanno Y, Muul L, O'Shea J. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. *Immunol Rev* 2004, **202**: 139-156.
7. Khader S, Partida-Sanchez S, Bell G, Jelley-Gibbs D, Swain S, Pearl J, *et al.* Interleukin 12p40 is required for dendritic cell migration and T cell priming after *Mycobacterium tuberculosis* infection. *J Exp Med* 2006, **203**: 1805-1815.
8. Robinson R, Khader S, Martino C, Fountain J, Teixeira-Coelho M, Pearl J, *et al.* *Mycobacterium tuberculosis* infection induces il12rb1 splicing to generate a novel IL-12Rβ1 isoform that enhances DC migration. *J Exp Med* 2010, **207**: 591-605.
9. Cooper AM. Cell mediated immune responses in tuberculosis. *Annu Rev Immunol* 2009, **27**: 393-422.
10. Orme I, Robinson R, Cooper A. The balance between protective and pathogenic immune responses in the TB infected lung. *Nat Immunol* 2015, **16**: 57-63.
11. Robinson R, Orme I, Cooper A. The onset of adaptive immunity in the mouse model of tuberculosis and the factors which compromise its expression. *Immunol Rev* 2015, **264**: 46-59.
12. Chackerian A, Alt J, Perera T, Dascher C, Behar S. Dissemination of *Mycobacterium tuberculosis* is influenced by host factors and precedes the initiation of T-cell immunity. *Infect Immun* 2002, **70**: 4501-4509.

- 480 13. Pearl JE, Torrado E, Tighe M, Fountain JJ, Solache A, Strutt T, *et al.* Nitric oxide inhibits the accumulation
481 of CD4⁺CD44^{hi}Tbet⁺CD69^{lo} T cells in mycobacterial infection. *Eur J Immunol* 2012, **42**: 3267-3279.
- 482
- 483 14. Chua AO, Wilkinson VL, Presky DH, Gubler U. Cloning and characterization of a mouse IL-12 receptor-beta
484 component. *J Immunol* 1995, **155**: 4286-4294.
- 485
- 486 15. Ray AA, Fountain JJ, Miller HE, Cooper AM, Robinson RT. IL12Rbeta1DeltaTM is a secreted product of
487 il12rb1 that promotes control of extra-pulmonary tuberculosis. *Infect Immun* 2015, **83**: 1230-1213.
- 488
- 489 16. Ford NR, Miller HE, Reeme AE, Waukau J, Bengtson C, Routes JM, *et al.* Inflammatory signals direct
490 expression of human IL12RB1 into multiple distinct isoforms. *J Immunol* 2012, **189**(9): 4684-4694.
- 491
- 492 17. Robinson RT. IL12Rbeta1: the cytokine receptor that we used to know. *Cytokine* 2015, **71**(2): 348-359.
- 493
- 494 18. Reeme A, Claeys T, Aggarwal P, Turner A, Routes J, Broeckel U, *et al.* Human IL12RB1 expression is allele-
495 biased and produces a novel IL12 response regulator. *Genes Immunit* 2018, **in press**.
- 496
- 497 19. Ramasamy A, Mondry A, Holmes CC, Altman DG. Key issues in conducting a meta-analysis of gene
498 expression microarray datasets. *PLoS Med* 2008, **5**(9): e184.
- 499
- 500 20. Voce DJ, Schmitt AM, Uppal A, McNERNEY ME, Bernal GM, Cahill KE, *et al.* Nfkb1 is a haploinsufficient DNA
501 damage-specific tumor suppressor. *Oncogene* 2015, **34**(21): 2807-2813.
- 502
- 503 21. Mondanelli G, Bianchi R, Pallotta MT, Orabona C, Albini E, Iacono A, *et al.* A Relay Pathway between
504 Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells.
505 *Immunity* 2017, **46**(2): 233-244.
- 506
- 507 22. Tian S, Krueger JG, Li K, Jabbari A, Brodmerkel C, Lowes MA, *et al.* Meta-analysis derived (MAD)
508 transcriptome of psoriasis defines the "core" pathogenesis of disease. *PLoS One* 2012, **7**(9): e44274.
- 509
- 510 23. Cliff JM, Kaufmann SH, McShane H, van Helden P, O'Garra A. The human immune response to tuberculosis
511 and its treatment: a view from the blood. *Immunol Rev* 2015, **264**(1): 88-102.
- 512
- 513 24. Cai Y, Yang Q, Tang Y, Zhang M, Liu H, Zhang G, *et al.* Increased complement C1q level marks active disease
514 in human tuberculosis. *PLoS One* 2014, **9**(3): e92340.
- 515
- 516 25. Pearl JE, Shabaana AK, Solache A, Gilmartin L, Ghilardi N, deSauvage F, *et al.* IL-27 signaling compromises
517 control of bacterial growth in mycobacteria-infected mice. *J Immunol* 2004, **173**: 7490-7496.

- 519 26. Robinson RT, Ray A, Chen X, Cooper A, inventors; Use of an IL12 Receptor-Beta 1 Splice Variant to Diagnose
520 Active Tuberculosis US. 2014.
- 521
- 522 27. Pashaei E, Guzel E, Ozgurses ME, Demirel G, Aydin N, Ozen M. A Meta-Analysis: Identification of Common
523 Mir-145 Target Genes that have Similar Behavior in Different GEO Datasets. *PLoS One* 2016, **11**(9):
524 e0161491.
- 525
- 526 28. Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor.
527 *Bioinformatics* 2007, **23**(14): 1846-1847.
- 528
- 529 29. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. *Bioinformatics* 2008, **24**(13):
530 1547-1548.
- 531
- 532 30. Singhania A, Verma R, Graham CM, Lee J, Trang T, Richardsdon M, *et al.* A modular transcriptional signature
533 identifies phenotypic heterogeneity of human tuberculosis infection. *bioRxiv* 2017.
- 534
- 535 31. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, *et al.* An interferon-inducible neutrophil-driven
536 blood transcriptional signature in human tuberculosis. *Nature* 2010, **466**: 973-977.
- 537
- 538 32. Ewels P, Magnusson M, Lundin S, Kaller M. MultiQC: summarize analysis results for multiple tools and
539 samples in a single report. *Bioinformatics* 2016, **32**(19): 3047-3048.
- 540
- 541 33. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*
542 2014, **30**(15): 2114-2120.
- 543
- 544 34. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. *Nat Methods*
545 2015, **12**(4): 357-360.
- 546
- 547 35. Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables improved
548 reconstruction of a transcriptome from RNA-seq reads. *Nat Biotechnol* 2015, **33**(3): 290-295.
- 549
- 550 36. Frazee AC, Pertea G, Jaffe AE, Langmead B, Salzberg SL, Leek JT. Ballgown bridges the gap between
551 transcriptome assembly and expression analysis. *Nat Biotechnol* 2015, **33**(3): 243-246.
- 552
- 553 37. Xia J, Wishart DS. Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis. *Curr Protoc*
554 *Bioinformatics* 2016, **55**: 14 10 11-14 10 91.
- 555
- 556 38. Medina E, North RJ. Resistance ranking of some common inbred mouse strains to *Mycobacterium*
557 *tuberculosis* and relationship to major histocompatibility complex haplotype and *Nramp1* genotype.
558 *Immunology* 1998, **93**: 270-274.

- 559
- 560 39. Kaforou M, Wright VJ, Oni T, French N, Anderson ST, Bangani N, *et al.* Detection of tuberculosis in HIV-
561 infected and -uninfected African adults using whole blood RNA expression signatures: a case-control
562 study. *Plos Medicine* 2013, **10**(10): e1001538.
- 563
- 564 40. Ottenhoff TH, Dass RH, Yang N, Zhang MM, Wong HE, Sahiratmadja E, *et al.* Genome-wide expression
565 profiling identifies type 1 interferon response pathways in active tuberculosis. *PLoS One* 2012, **7**(9):
566 e45839.
- 567
- 568 41. Cliff JM, Lee JS, Constantinou N, Cho JE, Clark TG, Ronacher K, *et al.* Distinct phases of blood gene
569 expression pattern through tuberculosis treatment reflect modulation of the humoral immune response.
570 *J Infect Dis* 2013, **207**(1): 18-29.
- 571
- 572 42. Reiley W, Calayag M, Wittmer S, Huntington J, Pearl J, Fountain J, *et al.* ESAT-6-specific CD4 T cell
573 responses to aerosol *Mycobacterium tuberculosis* infection are initiated in mediastinal lymph nodes. *PNAS*
574 2008, **105**: 10961-10966.
- 575
- 576 43. Domingo-Gonzalez R, Prince O, Cooper A, Khader SA. Cytokines and Chemokines in *Mycobacterium*
577 tuberculosis Infection. *Microbiol Spectr* 2016, **4**(5).
- 578
- 579 44. Mayer-Barber KD, Andrade BB, Barber DL, Hieny S, Feng CG, Caspar P, *et al.* Innate and adaptive
580 interferons suppress IL-1α and IL-1β production by distinct pulmonary myeloid subsets during
581 *Mycobacterium tuberculosis* infection. *Immunity* 2011, **35**: 1023-1034.
- 582
- 583 45. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, *et al.* Host-directed therapy
584 of tuberculosis based on interleukin-1 and type I interferon crosstalk. *Nature* 2014, **511**(7507): 99-103.
- 585
- 586 46. McNab FW, Ewbank J, Howes A, Moreira-Teixeira L, Martirosyan A, Ghilardi N, *et al.* Type I IFN induces IL-
587 10 production in an IL-27-independent manner and blocks responsiveness to IFN-γ for production of IL-
588 12 and bacterial killing in *Mycobacterium tuberculosis*-infected macrophages. *J Immunol* 2014, **193**(7):
589 3600-3612.
- 590
- 591 47. Turner AJ, Aggarwal P, Miller HE, Waukau J, Routes JM, Broeckel U, *et al.* The introduction of RNA-DNA
592 differences underlies interindividual variation in the human IL12RB1 mRNA repertoire. *Proc Natl Acad Sci*
593 *U S A* 2015, **112**(50): 15414-15419.
- 594
- 595 48. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. *Nat Rev*
596 *Immunol* 2015, **15**(2): 87-103.
- 597
- 598

Figure 1 Das et al

Figure 2 Das et al

Figure 3 Das et al

Figure 4 Das et al

Figure 5 Das et al

Table 1: The demographic characteristics of study population Shenzhen Third Peoples Hospital in Shenzhen, China.

Study Cohort	n	Median age in years (range)	Gender (M/F)	AFB-positive	ELISPOT Positive
TB	20	38.2 (25.0-58.0)	13/7	20	20
LTBI	20	31.2 (23.0-56.0)	12/8	ND ¹	20
HC	20	28.6 (21.0-48.0)	10/10	ND	0
Pneumonia	20	39.2 (29.0-59.0)	12/8	ND	ND

¹ND = not done

Table 2. Details of the public array data assessed for expression of the Δ TM-IL-12R β 1

bioRxiv preprint doi: <https://doi.org/10.1101/271627>; this version posted February 26, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

	GEO dataset	Platform	Pathology (no of sample used; Location)	Sample	Reference
1	GSE19444	GPL6947: Illumina HumanHT-12 V3.0 expression beadchip	PTB (21; UK) LTB ^{T&I} (21; UK) CON ^{T&I} (12;UK)	Whole blood	Berry et al (2010) Nature 466:973-977
2	GSE19443	GPL6947: Illumina HumanHT-12 V3.0 expression beadchip	PTB (7; UK) CON ^{T&I} (4; UK)	Neutrophil, Monocyte, CD4 and CD8 cells purified from whole blood	Berry et al (2010) Nature 466:973-977
3	GSE19442	GPL6947: Illumina HumanHT-12 V3.0 expression beadchip	PTB (20, SA) LTB ^I (31, SA)	Whole blood	Berry et al (2010) Nature 466:973-977
4	GSE19439	GPL6947: Illumina HumanHT-12 V3.0 expression beadchip	PTB (13; UK) LTB ^{T&I} (17; UK) CON ^{T&I} (12;UK)	Whole blood	Berry et al (2010) Nature 466:973-977
5	GSE19435	GPL6947: Illumina HumanHT-12 V3.0 expression beadchip	PTB (7; UK) PTB_long_2M (7; UK) PTB_long_12M (7; UK) CON ^{T&I} (12;UK)	Whole blood	Berry et al (2010) Nature 466:973-977
6	GSE37250	GPL10558: Illumina HumanHT-12 V4.0 expression beadchip	PTB (47; SA) (59; Malawi) LTB ^{T&I} (50; SA) (36; Malawi)	Whole blood	Kaforou et al (2013) PLoS Med 10:e1001538.
7	GSE56153	GPL6883: Illumina HumanRef-8 v3.0 expression beadchip	PTB (18, Indonesia) TREAT (15; Indonesia) RECO (20; Indonesia) CON ND (18; Indonesia)	Whole blood	Ottenhoff et al (2012) PLoS ONE 7: e45839
8	GSE54992	GPL570: Affymetrix Human Genome U133 Plus 2.0 Array	PTB (9; China) PTB_long_3M (9; China) PTB_long_6M (9; China) LTB ^I (6; China) CON ^I (6; China)	Peripheral blood mononuclear cells	Cai et al (2014) PLoS One 9:e92340
9	GSE36238	GPL570: Affymetrix Human Genome U133 Plus 2.0 Array	PTB (27; SA) PTB_long_6M (27; SA)	Whole blood	Cliff et al (2013) J Infect Dis 207:18-29.
10	GSE31348	GPL570: Affymetrix Human Genome U133 Plus 2.0 Array	PTB (27; SA) PTB_long_1W (27; SA) PTB_long_2W (27; SA) PTB_long_1M (27; SA) PTB_long_6M (27; SA)	Whole blood	Cliff et al (2013) J Infect Dis 207:18-29.

PTB: Pulmonary TB

LTB: Latent TB diagnosed with tuberculin skin test (TST) and IGRA (LTB^{T&I}) or Latent TB diagnosed with IGRA only (LTB^I).

CON: Healthy control with negative latent infection diagnosed with tuberculin skin test (TST) and IGRA (CON^{T&I}) or IGRA only (CON^I) or latency not determined (CONND)

PTB long: Pulmonary TB subject undergoing treatment. Samples collected at 1week (1W), 2 weeks (2W), 1 month (1M), 2 months (2M), 6 months (6M) and 12 months (12M).

Table 3. The signal from probes specific for the Δ TM-IL-12R β 1 isoform in microarray data sets correlates with the majority of signal seen for all of the IL-12R β 1 targeted probes.

Array data set	Correlation coefficient between the signal for probes specific for:		
	Δ TM-IL-12R β 1 and all probes	Δ TM-IL-12R β 1 and IL-12R β 1 full-length	IL-12R β 1 full-length and all probes
GSE19444	0.66 ¹	0.43	0.32
GSE19442	0.44	-0.16	-0.09
GSE56153	0.89	0.67	0.68
GSE54992	0.51	0.16	0.05

¹ Normalised fluorescent intensities of probes specific for different isoforms of IL-12R β 1 were used to prepare a matrix and the Pearson correlation coefficient was calculated using online tool Metaboanalyst 3.0.

Table 4. Discriminatory potential of IL-12-related variables for identifying disease groups.

Variables which include the signal from the Δ TM-IL-12R β 1 occur as one of the top 3 variables IL-12-related discriminator in each comparison. The top 3 variables based on area under curve (AUC) for each comparison is shown.

	PTB CON	AUC	p-value	LTB PTB	AUC	p-value	LTB CON	AUC	p-value
GSE19444	(Δ TM +All)/2	0.73	0.01	Δ TM	0.60	0.37	(Δ TM +All)/2	0.72	0.03
	All	0.72	0.02	IL12a	0.58	0.31	Δ TM	0.71	0.04
	Δ TM	0.71	0.02	(Δ TM +All)/2	0.57	0.38	All	0.70	0.06
GSE19439	(Δ TM +All)/2	0.93	0.00	Δ TM	0.76	0.01	Δ TM /Full	0.88	0.00
	Δ TM	0.90	0.00	(Δ TM +All)/2	0.74	0.02	Full	0.78	0.02
	Δ TM /Full	0.87	0.00	Δ TM/IL12Rb2	0.74	0.01	Δ TM	0.76	0.01
GSE54992	Δ TM	1.00	0.00	Δ TM	1.00	0.00	IL12Rb2	0.78	0.13
	(Δ TM +All)/2	1.00	0.00	avg_dTM_all3	1.00	0.00	Δ TM /IL12Rb2	0.75	0.13
	Δ TM /Full	1.00	0.00	Δ TM /Full	1.00	0.00	IL12b	0.72	0.18

Δ TM: Probe intensity for Δ TM-IL-12R β 1 isoform,

All: Intensity of probe specific for both isoforms of 12R β 1;

Full: Intensity of probe specific for full length 12R β 1 isoform.